Advanced Search Results For "Intraocular Pressure drug effects"
Your filters
Effect of intravenous induction with different doses of Esketamine combined with propofol and sufentanil on intraocular pressure among pediatric strabismus surgery: a randomized clinical trial.
Publication Type: Academic Journal
Source(s): BMC anesthesiology [BMC Anesthesiol] 2023 Aug 15; Vol. 23 (1), pp. 275. Date of Electronic Publication: 2023 Aug 15.
Abstract: Background: It is well-established that maintaining stable intraocular pressure (IOP) within the normal range during ophthalmic surgery is important. Esketamine is a commonly used drug in pediatric general anesthesia due to its good analgesic and sedat...
Treatment and outcome of IgA nephropathy in children from one single center experience.
Publication Type: Academic Journal
Source(s): BMC pediatrics [BMC Pediatr] 2023 Jul 26; Vol. 23 (1), pp. 377. Date of Electronic Publication: 2023 Jul 26.
Abstract: Background: There is no standard recommendation for IgA nephropathy treatment in children.Methods: This is a retrospective study. From 2012 to 2020, newly diagnosed primary IgAN followed up for at least 1 year were enrolled. The correlation of MESTC sc...
Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
Publication Type: Academic Journal
Source(s): British journal of haematology [Br J Haematol] 2022 Mar; Vol. 196 (5), pp. 1248-1256. Date of Electronic Publication: 2021 Dec 04.
Abstract: Most childhood acute lymphoblastic leukaemia (ALL) protocols include high-dose steroid therapy. However, the known potential of high-dose steroids to significantly elevate intraocular pressure (IOP) and lead to glaucomatous optic neuropathy has not bee...
Glypican-4 regulated actin cytoskeletal reorganization in glucocorticoid treated trabecular meshwork cells and involvement of Wnt/PCP signaling.
Publication Type: Academic Journal
Source(s): Journal of cellular physiology [J Cell Physiol] 2023 Mar; Vol. 238 (3), pp. 631-646. Date of Electronic Publication: 2023 Feb 02.
Abstract: A common adverse response to the clinical use of glucocorticoids (GCs) is elevated intraocular pressure (IOP) which is a major risk factor for glaucoma. Elevated IOP arises due to impaired outflow of aqueous humor (AH) through the trabecular meshwork (...
Relationships between Intraocular Pressure, Effective Filtration Area, and Morphological Changes in the Trabecular Meshwork of Steroid-Induced Ocular Hypertensive Mouse Eyes.
Publication Type: Academic Journal
Source(s): International journal of molecular sciences [Int J Mol Sci] 2022 Jan 13; Vol. 23 (2). Date of Electronic Publication: 2022 Jan 13.
Abstract: We investigated whether an inverse relationship exists between intraocular pressure (IOP) and effective filtration area (EFA) in the trabecular meshwork (TM) in a steroid-induced ocular hypertensive (SIOH) mouse model and the morphological changes asso...
Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study.
Publication Type: Academic Journal
Source(s): Acta ophthalmologica [Acta Ophthalmol] 2022 Mar; Vol. 100 (2), pp. e470-e477. Date of Electronic Publication: 2021 Jul 28.
Abstract: Purpose: To evaluate ocular hypotensive efficacy and the safety of sovesudil (formally known as PHP-201), a novel Rho-associated protein kinase (ROCK) inhibitor, in patients with normal-tension glaucoma (NTG).Design: Multicentre, prospective, double-ma...
Morphological changes in the trabecular meshwork and Schlemm's canal after treatment with topical intraocular pressure-lowering agents.
Publication Type: Academic Journal
Source(s): Scientific reports [Sci Rep] 2021 Sep 13; Vol. 11 (1), pp. 18169. Date of Electronic Publication: 2021 Sep 13.
Abstract: Glaucoma treatment is usually initiated with topical medication that lowers the intraocular pressure (IOP) by reducing the aqueous production, enhancing the aqueous outflow, or both. However, the effect of topical IOP-lowering medications on the micros...
Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.
Publication Type: Academic Journal
Source(s): Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 613-623.
Abstract: Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred method to treat glaucoma, eye drops...
LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY.
Publication Type: Academic Journal
Source(s): Retina (Philadelphia, Pa.) [Retina] 2021 Jul 01; Vol. 41 (7), pp. 1438-1445.
Abstract: Purpose: To analyze the incidence, risk factors, and time to onset of ocular hypertension (OHT) after intravitreal injections (IVI) of dexamethasone implant and to evaluate the long-term cumulative probability of intraocular pressure elevation.Methods:...
In Situ Gelling Electrospun Ocular Films Sustain the Intraocular Pressure-Lowering Effect of Timolol Maleate: In Vitro, Ex Vivo, and Pharmacodynamic Assessment.
Publication Type: Academic Journal
Source(s): Molecular pharmaceutics [Mol Pharm] 2022 Jan 03; Vol. 19 (1), pp. 274-286. Date of Electronic Publication: 2021 Dec 08.
Abstract: Most common intraocular pressure (IOP) reduction regimens for the management of glaucoma include the topical use of eye drops, a dosage form that is associated with short residence time at the site of action, increased dosing frequency, and reduced pat...